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Purpose: To increase access of underserved/health disparities communities to National
Cancer Institute (NCI) clinical trials, the Radiation Research Program piloted a unique
model – the Cancer Disparities Research Partnership (CDRP) program. CDRP targeted com-
munity hospitals with a limited past NCI funding history and provided funding to establish
the infrastructure for their clinical research program.
Methods: Initially, 5-year planning phase funding was awarded to six CDRP institutions
through a cooperative agreement (U56). Five were subsequently eligible to compete for 5-
year implementation phase (U54) funding and three received a second award. Additionally,
the NCI Center to Reduce Cancer Health Disparities supported their U56 patient navigation
programs.
Results: Community-based hospitals with little or no clinical trials experience required at
least a year to develop the infrastructure and establish community outreach/education and
patient navigation programs before accrual to clinical trials could begin. Once established,
CDRP sites increased their yearly patient accrual mainly to NCI-sponsored cooperative
group trials (~60%) and Principal Investigator/mentor-initiated trials (~30%).The total num-
ber of patients accrued on all types of trials was 2,371, while 5,147 patients received
navigation services.
Conclusion: Despite a historical gap in participation in clinical cancer research, under-
served communities are willing/eager to participate. Since a limited number of cooperative
group trials address locally advanced diseases seen in health disparities populations; this
shortcoming needs to be rectified. Sustainability for these programs remains a challenge.
Addressing these gaps through research and public health mechanisms may have an impor-
tant impact on their health, scientific progress, and efforts to increase diversity in NCI
clinical trials.
Keywords: cancer disparities, underserved populations, patient accrual, access to clinical trials, clinical research
INTRODUCTION
The Cancer Disparities Research Partnership (CDRP) pilot pro-
gram was initiated by the radiation research program (RRP)
within the National Cancer Institute (NCI)’s Division of Can-
cer Treatment and Diagnosis (DCTD) in 2002 as a novel strategy
to address the cancer health disparities that exist in racial, ethnic,
Abbreviations: ACS,American Cancer Society; AI,American Indian; ASTRO,Amer-
ican Society for Radiation Oncology; ATM, ataxia telangiectasia mutated gene;
BSA, Board of Scientific Advisors for National Cancer Institute; CCRO, Coastal
Carolina Radiation Oncology; CCOP, Community Clinical Oncology Program;
CDRP, Cancer Disparities Research Partnership; CRCHD, Center to Reduce Can-
cer Health Disparities; CRR, Community Research Representative; CTOC, Clinical
Trials Operating Committee; DCTD, Division of Cancer Treatment and Diagnosis;
IAEA, International Atomic Energy Agency; IRB, Institutional Review Board; MB-
CCOP, Minority-Based Community Clinical Oncology Program; NACR, Native
minority, and underserved populations within the United States
(1). Over half of all cancer patients are treated with radiation
alone or in combination with surgery or chemotherapy. This
program was focused at radiation oncologists in community-
based hospitals and cancer centers that predominantly serve
minority/underserved populations. Since the goal was to reach
American Cancer Research; NCI, National Cancer Institute; NCORP, National
Cancer Institute Community Oncology Research Program; NHRMC, New Han-
nover Regional Medical Center; NIH, National Institute of Health; PACT, Pro-
gram of Action for Cancer Therapy; PI, principal investigator; RCRH, Rapid
City Regional Hospital; RFA, request for application; RRP, Radiation Research
Program; RTOG, radiation therapy oncology group; SENC, Southeastern North
Carolina; SRHS, Singing River Health System; UAB, University of Alabama Birm-
ingham; UPMC, University of Pittsburgh Medical Center; WFP, Walking Forward
Program.
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populations not having access to NCI clinical trials, application cri-
teria included limited participation in clinical trials, and NCI grant
funding <$100,000/year. Utilizing a U56 planning cooperative
agreement, funding went directly to community-based institu-
tions to establish the clinical research infrastructure required for
their populations to access NCI-sponsored radiation oncology-
based clinical trials. CDRP sites were required to identify academic
cancer centers or mentors experienced in NCI-sponsored clinical
trials as partners who received limited funding from the grantee.
To facilitate the mentoring relationships, a TELESYNERGY™ (2),
telemedicine system was provided to both grantee and primary
mentor. Furthermore, NCI’s Center to Reduce Cancer Health Dis-
parities (CRCHD) provided supplemental funding to establish
a patient navigation program addressing the specific needs of
grantee’s targeted populations.
The primary goal was to increase accrual of minority/under-
served populations into NCI-sponsored clinical trials. Other
objectives were: (1) increasing the number of staff involved in
cancer health disparities research; (2) assessing the value of imple-
menting the TELESYNERGY™ telemedicine system; (3) imple-
menting an appropriate patient navigation program; and (4)
determining whether this pilot would work in community-based
institutions not historically involved in clinical research.
MATERIALS AND METHODS
PROCESS FOR APPROVAL OF CDRP CONCEPT INITIATIVE AND
REISSUANCE
Following an NIH/NCI portfolio analysis, which determined a
need for the proposed program, the CDRP concept was approved
by the NCI’s Board of Scientific Advisors and the request for
application (RFA-CA-02-002), was issued in October 2001. An
NCI Special Emphasis Panel reviewed six applications and two
awards were made in September 2002. Since initial funding
was approved for up to six awards, RFA-CA-03-018 was issued
in August 2002 and four additional awards were made out of
eight reviewed applications producing a success rate of 43%
from both RFAs. Table 1 includes information on the grantees,
Principal Investigators (PIs), mentors, service areas, and target
populations.
The formal process for reissuance of any currently funded
NCI program changed in 2006 and required an external pro-
gram evaluation. NOVA Research Company (3) was awarded the
5-year U56 CDRP Process and Outcome Evaluation contract,
which helped generate the programmatic assessment data. The
reissuance process used NOVA’s yearly CDRP Program Evalua-
tion Reports (2006–2008) containing qualitative and quantitative
data and the evaluation report by the CDRP Program Expert
Committee (see Supplementary Material). This Expert Committee
and CDRP PIs met annually at the American Society for Radi-
ation Oncology (ASTRO) meeting to help RRP evaluate yearly
progress and make recommendations for program improvement.
The BSA recommended not expanding the program, but to accept
applications only from the five funded grantees in a limited
competition RFA-CA-09-502 (October 2008). After the Special
Emphasis Panel review, 5-year U54 implementation awards were
made to Rapid City Regional Hospital (RCRH), New Hanover
Regional Medical Center (NHRMC), and Singing River Health
System (SRHS), while UPMC McKeesport Hospital received a
2-year phase out award.
METRICS OF SUCCESS
The metrics of success were:
1) Could a community-based hospital/cancer center establish a
clinical research infrastructure within a reasonable period and
accrue patients into radiation oncology-based clinical trials?
2) Was participation of underserved populations in NCI-
sponsored clinical trials increased?
3) Were mentors helpful in providing necessary training, support,
and advice to the grantees?
4) Was the TELESYNERGY™ telemedicine system beneficial to
the CDRP programs?
5) Was the CDRP grantee successful in increasing the number of
physicians/other staff interested in cancer disparities research?
6) Was the CDRP site successful in disseminating program results
through publications/presentations at national meetings?
RESULTS
ESTABLISHMENT OF INFRASTRUCTURE
Establishing the clinical research infrastructure was challeng-
ing because institutions were unfamiliar with its value for their
patients. Despite all PIs having prior clinical trials experience, it
took many months to educate the hospital administration about
the benefits for their patients by participating in NCI clinical trials.
By offering trials near their hometowns, patients can access these
clinical advances without traveling great distances.
Findings from the U56 pilot program revealed important and
unique issues regarding outreach to disparities populations not
encountered at academic cancer centers and their community
oncology affiliates. Disparities researchers needed sufficient time
to succeed in: (1) recruiting personnel due to challenges in finding
qualified staff to fill positions (e.g., program/grant manager, clin-
ical research nurse/coordinator, data manager, patient navigator,
and regulatory affairs expert for writing clinical protocols); (2)
identifying a back-up PI after the loss of the primary PI at Laredo
Medical Center; (3) establishing an outreach program so the com-
munity gained familiarity and trust with the PI and the research
team (4, 5); and (4) surveying the populations to determine their
knowledge, attitudes, perceived barriers, and needs.
PARTICIPATION IN CLINICAL TRIALS
After the infrastructure was established, there was steady patient
accrual onto various NCI clinical trials (Table 2). The type of tri-
als most useful to the grantees is discussed below. The fluctuation
seen in patient accruals was due to the limited number of cooper-
ative group trials available for minority/underserved populations
presenting with late-stage disease and co-morbidities. The restric-
tive eligibility criteria for many cooperative group trials resulted
in low eligibility rates, averaging only 20–24% during both U56
and U54 phases (Table 3) (6).
MENTORING AND PARTNERSHIP
All grantees selected an NCI-designated Comprehensive Cancer
Center as a primary or secondary (Laredo) mentor (Table 1)
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Table 1 | CDRP grantees, program title, PIs, mentors, service areas, and their target populations.
Award year Grantee/principal investigator (PI) Service area
population
Target population
FY02 Rapid City Regional Hospital, Rapid City, South Dakota
Program name: Walking Forward (WF)a
PI: Daniel G. Petereit, MD
Primary mentor: University of Wisconsin-Madison
Secondary mentor: Mayo Clinic in Rochester, MN
300,000 American Indian/Native
American
FY02 Laredo Medical Centerb; Laredo, Texas
Program name: Evaluating Cancer Disparities Among Hispanic Communities
PI: Yadvindera S. Bains, MD
Primary mentor: University of Texas Health Science Center
Secondary mentor: MD Anderson Cancer Center in Houston, TX
177,000 Hispanic/Latino
FY03 Daniel Freeman Memorial Hospitalc
Inglewood, CA, USA
Program name: Urban Latino African American Cancer (ULAAC) Disparities Project
PI: Michael L. Steinberg, MDd
Primary Mentor: University of Southern California
Secondary Mentor: RAND Corporation, Santa Monica, CA
100,000 African American
Hispanic/Latino
FY03 New Hanover Regional Medical Center
Wilmington, North Carolina
Program name: Improving Cancer Outcomes for African-Americans
PI: Patrick D. Maguire, MD
Primary mentor: University of North Carolina-Chapel Hill
616,000 African American
Urban/Rural Poor
FY03 Singing River Hospital; Pascagoula, Mississippi
Program name: The Mississippi/Alabama Radiation Oncology Research Partnership
PI: Raymond Wynn, MDe
Primary mentor: University of Alabama at Birmingham
Secondary mentor: University of Mississippi Medical Center
200,000 African American
FY03 University of Pittsburgh Medical Center (UPMC) McKeesport Hospital; McKeesport,
Pennsylvania
Program name: Radiation Oncology Community Outreach Group (ROCOG)
PI: Dwight E. Heron, MD
Primary mentor: Washington University, St. Louis, MO, USA
Secondary Mentor: Roswell Park Cancer Center, Buffalo, NY
935,000 African American
Urban/Rural Poor
aRapid City changed its CDRP program name early in program development from “Enhancing Native American Participation in Radiation Therapy Trials” to “Walking
Forward,” which was considered more culturally appropriate for their target American Indian patients.
bCDRP grant was relinquished in 2007 due to inability to find a qualified radiation oncologist to become PI when original PI resigned in 2006.
cGrant was changed to Centinela Freeman in 2004 and later was transitioned toTwenty-First Century Oncology at the Santa Monica CancerTreatment Center in 2008.
dDr. David Khan is the current CDRP PI and Dr. Michael Steinberg is co-PI.
eDr. Raymond Wynn resigned in 2005 and Dr. W. Sam Dennis became the new PI.
based on clinical research expertise and/or an existing relationship;
many also selected secondary partners to address specific needs.
An important lesson learned was the need for the grantee to work
immediately with the academic center’s grants research office to
obtain details on job descriptions, guidance for establishing an
Institutional Review Board (IRB), and assistance in grant man-
agement. Given the complexity of a clinical trials infrastructure,
grantees required a year or more before their disparity program
was fully operational leading some to restructure their awards to
allow an additional year.
DEVELOPING CANCER DISPARITIES RESEARCH INTEREST AND
PATIENT NAVIGATION
Because of the limited availability of cooperative group trials
as noted above, the grantees used two approaches to expand
protocol participation: (1) development of PI-initiated clinical tri-
als targeting stage of disease and/or including shorter radiation
therapy schedules to address patients’ transportation or accom-
modations barriers (7, 8) and (2) expanding access to other NCI-
sponsored clinical trials beyond radiation oncology, to include
surgical/medical oncology trials (Table 2). This expansion was
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Table 2 | Cumulative number of patients accrued to different types of clinical trials by fiscal year in U56 planning phase and cumulative for U54
phase.
Type of clinical trial FY03a FY04 FY05 FY06 FY07 FY08 FY09 Total U56 periodb (%) Total U54 Periodc (%)
PI-initiated 0 1 44 78 78 38 62 301 (18) 139 (20)
Mentor-initiated 0 0 0 0 0 0 160 160 (10) 203 (29)
RTOG 10 7 17 26 34 24 50 168 (10) 128 (19)
Other cooperative groupsd 271 349 39 75 84 98 82 998 (60) 209 (30)d
Radiation only 1 0 4 20 9 0 3 37 (4) -
Radiation/combined treatment 65 9 14 24 19 13 14 158 (16) -
Medical/surgical 140 25 24 27 55 79 57 407 (41) -
Cancer control/prevention 75 316e 6 9 10 11 14 441 (44) 71 (45f)
Pharmaceutical/industry 0 0 5 1 8 6 31 51 (3) 14 (2)
Total 281a 357 105 180 204 166 385 1,678 (100g) 693 (100g)
aRapid City had approximately 33 active clinical protocols opened during FY03 in which they accrued 281 patients onto the STAR trial and cooperative group trials
(RTOG and NCCTG) (n=281).
bU56 data are through September 30, 2009.
cData cumulative for FY2010 through 2013 for all U54 grantees.
dRapid City data include patients who were enrolled onto both RTOG and other cooperative group trials. The database structure at this site did not allow segregating
the different trial categories (e.g., radiation only, medical/surgical) by only cooperative group trials. For U54 grantees, segregation was also not done.
eIncludes Laredo’s accruals to NCI prevention trials, STAR (n=9), and SABOR (300).
fPercent accrual to prevention trials out of total NCI cooperative group trial accruals.
gColumn percents do not total 100% due to rounding.
Table 3 | Number of patients screened and eligible for cancer clinical
trials.
Grantee sitesa Patients
screened
Patients
eligible
Eligibility
rateb (%)
(U56)c (U54)d (U56) (U54) (U56) (U54)
Rapid City 1,601 3180 457 340 29 11
Centinela Freeman 28 – 28 – 100e –
New Hanover 228 2578 84 839 37 33
Singing River 982 2396 166 371 17 16
UPMC McKeesport 637 376 84 29 13f 8f
Total 3,476 8530 819 1579 24 20
aData were not available for Laredo.
bEligibility rate is based on the number of patients eligible divided by the number
of patients screened.
cU56 data are from FY07 through FY09 only.
dData cumulative for FY2010 through 2013 for all U54 grantees.
eCentinela Freeman did not screen all patients.
fOnly includes data on the UPMC McKeesport site out of a total of five
participating hospital at this CDRP site.
facilitated starting in 2006 by Clinical Trial Operating Commit-
tee (CTOC) supplemental awards to RCRH, SRHS, and UPMC
McKeesport for hiring clinical staff interacting with other oncol-
ogy specialists and resulted in increased annual patient accruals
(Table 2).
Having breadth in the portfolio of trials was critical to over-
all participation as shown in Table 2. Early on, prevention trials
boosted accrual (FY03-04), but later on the increased accrual
(FY06 onward) was due to availability of non-radiation trials.
A total of 2,371 patients were accrued during both phases. The
PI/mentor-initiated trials (see Supplementary Material) partially
addressed the shortfall of trials suitable for this population as
ineligibility remained an accrual barrier (Table 3).
In addition to informing patients about the clinical trials, the
patient navigators supported by CRCHD had a positive influence
on reducing the number of missed appointments and addressing
other barriers to patient participation (9–11). Patient navigation
was found to be a critical component at all CDRP sites as 5,147
patients were navigated (Table 4). RCRH and SRHS documented
the critical benefit of patient navigators for their patients. Their
data helped RCRH to receive a subsequent Komen Foundation
grant specifically for a patient navigator to assist all their breast
cancer patients, while SRHS’s patient navigator became a hospital
funded position starting in 2011.
The American Indian (AI) Community Research Representa-
tives (CRRs) were established with CDRP funding at three remote
AI reservations in South Dakota. These trained community health
educators and Patient Navigators helped RCRH receive a 2-year
CDC grant by partnering with the South Dakota Health Depart-
ment utilizing their CRRs to implement a colorectal screening
program for their AI population. Additionally, RCRH partnered
with the American Cancer Society to implement the “All Women
Count!” Breast and Cervical Cancer Early Detection Program for
their AI women at the Pine Ridge Indian Reservation whereby the
goals of both ACS and RCRH’s Walking Forward Program were
implemented (Dr. Petereit, personal communication, April 2014).
TELESYNERGY™ – TELEMEDICINE AND EMPLOYMENT
OPPORTUNITIES IN REMOTE COMMUNITIES
When the CDRP program was initiated, telemedicine was just
being established and this program became a pilot test for
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Table 4 | Number of navigated patients per fiscal year by CDRP grantee.
Grantee sites FY04 FY05 FY06 FY07 FY08 FY09 U56 total #a U54 total #b
Rapid City 35 77 56 66 184 211 629 786
Laredoc 183 74 90 NA NA NA 347 NA
Centinela Freeman NAd 80 146 166 90 127 609 NA
New Hanover 2 17 103 117 87 48 374 276
Singing River NC NR NR 208 142 325 675 526
UPMC McKeesport NAd 96 165 252 217 116 846 79
Total 220 344 560 809 720 827 3,480 1,667
NA, not applicable; NC, data not collected by CDRP site; NR, refers to data not received.
aU56 data were consistently collected beginning in FY2007, Quarter 4 through September 30, 2009.
bData cumulative for FY2010 through FY2013 for all U54 grantees.
cLaredo data are unconfirmed.
dPatient navigation program was not active until 2005.
Table 5 | Use ofTELESYNERGY™ for CDRP grantee activities, by fiscal
year – U56 phase*.
CDRP grantee activity Number of times used for activity
FY07, Qtr 4 FY08 FY09 Total
Administrative meetings 5 29 28 62
Research consultations 21 8 16 45
Patient consultations 612 2,037 237 2,886a
Tumor boards 12 113 108 233
Training/education 5 10 20 35
Otherb 8 4 14 26
Total 663 2,201 423 3,287
*Data were consistently collected beginning in FY2007, quarter 4 through
September 30, 2009.
a99% of the patient consultations via TELESYNERGY® were conducted by Rapid
City.
bIncludes TELESYNERGY® maintenance and patient rounds.
TELESYNERGY™, a system developed jointly by the NIH Cen-
ter for Information Technology and NCI. Table 5 details how it
was used. Videoconferencing facilitated communication between
awardees and their mentors for treatment planning (12) and
follow-up consultations at remote settings (e.g., South Dakota
and Pennsylvania). It was also used among CDRP sites predomi-
nantly for training clinical research staff, tumor board conferences,
research consultations, and sharing of ideas. Establishing clini-
cal consultation sites at remote centers resulted in saved patient
travel time, and it also provided employment opportunities for
healthcare workers on the reservations and at satellite Pennsyl-
vania hospitals. These successes were important lessons learned
from the conduct of clinical trials and medical care for remote
disparities communities (12–14).
DISSEMINATION OF RESULTS
The CDRP institutions were very active in presentations at local
meetings and nationally at the Radiation Therapy Oncology
Table 6 | Number of CDRP-related publications by grantee site.
Grantee Number of
publications
U56 U54
Laredo 1 NA
Rapid City 23a 24
Centinela Freeman 8 NA
New Hanover 4 4
Singing River 3 0
UPMC McKeesport 14 3
Total 53 31
aIncludes three book chapters.
Group (now part of NRG Oncology) and the annual ASTRO
meetings. Additionally, the CDRP program helped establish an
annual ASTRO/NCI Cancer Disparity Symposium to help edu-
cate members about cancer disparities issues in the U.S. (see
Supplementary Material). All CDRP sites were active to vari-
ous degrees in publishing results of their cancer disparities pro-
gram with RCRH being the most productive with publications
(Table 6).
DISCUSSION
As pointed out in a BSA discussion, CDRP took on some of the
most difficult challenges to develop clinical trials because of both
the disparity populations and the limited previous NIH funding
history. Although a higher level of trial participation may have
been possible with health disparities sites within the catchment of
an NCI-designated Cancer Center and the Division of Cancer Pre-
vention’s Minority-Based Community Clinical Oncology Program
site, that CDRP successfully reached into the more difficult-to-
reach areas dispelled the concept that this was impossible and/or
that people would reject participation in trials.
To expect health disparities sites to achieve similar rates of clini-
cal trial accrual as major cancer centers and their catchment area is
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not realistic. Implementation takes time and include: (1) develop-
ing/training personnel with the necessary research skills and staff
to work with government regulations for clinical trials; (2) advising
administrators and hospital leadership about the patience needed
to develop infrastructure and the wisdom to see the benefit to
patients and institution; and (3) establishing physical space and
technological facilities needed to conduct research and manage
the data.
Having an experienced team from NCI initiate the programs
with a visit to the institution was also important. Although there
was skepticism based on the experiences that the government
would “establish a program, do research, and then leave (14),”
this support helped establish trust and personal relationships
demonstrating that the government was invested in the commu-
nity’s problems. The initial NCI team included physicians, senior
administrators, program directors, and a patient advocate pro-
vided by the National Coalition for Cancer Survivorship (15) who
emphasized the central importance of community buy-in at the
outset.
We suggest that the proposed metrics of success for future dis-
parities efforts include the usual “hard” metrics such as clinical
trial participation and publications, but also softer metrics such
as: (1) surveys conducted, (2) the number of patients screened,
(3) the extent of outreach–recruitment activity, (4) additional
research efforts leveraging their infrastructure, (5) staff recruit-
ment, (6) enhanced interest in disparities by cooperative groups
(e.g., RTOG) and professional societies (ASTRO), and (7) the abil-
ity to secure additional funding. Formal program evaluation as
established by NOVA was extraordinarily helpful for the awardees
and RRP in assessing progress and determining both gaps and
opportunities for progress. The CDRP programs shared data and
trials among the awardees, which facilitated the implementation
science.
Several years are needed to ramp up clinical trial participa-
tion, including the need for surveys and focus groups, time to
listen to the community, understanding their needs, assessing bar-
riers and building teams and trust (5, 16). Establishing trusting
partnerships with the AI community in SD was a potential bar-
rier for the Walking Forward (WF) program that was successfully
addressed over time and became evident when there was no dif-
ficulty in consenting patients to participate in the ATM genetic
study (17). For the advanced stage diseases encountered in minor-
ity/underserved populations and limited number of cooperative
group studies available, designing PI- and mentor-initiated trials
and the later expansion to a broader portfolio of trials beyond
radiation oncology resulted in increased accrual for these patient
populations (Table 2).
Telemedicine has evolved significantly as the TELESYNERGY™
system progressed from expensive ISDN phone line systems to a
web-based system using off-the-shelf technology. A simplified ver-
sion is now available for public purchase by outside institutions,
both nationally and internationally, with the possibility for sup-
port for technical consultations, installation, and training from
NIH/NCI if needed.
The establishment of CDRP led to some important changes
in the radiation oncology community. The RTOG (now part
of NRG Oncology) raised the issue of the need for future
“health disparities” clinical trials to fill the gaps noted above.
ASTRO developed an annual health disparities scientific program
(see Supplementary Material) and additional radiation oncol-
ogy activities related to cancer disparities on the international
level include working with the Program of Action for Cancer
Therapy (PACT) of the International Atomic Energy Agency
(IAEA) (18)
Perhaps, the greatest challenge now is program sustainabil-
ity. There were positive outcomes that were not predicted and
are strong evidence of the value of investing in NIH/NCI clinical
research in health disparities regions. Examples are provided from
the three 10-year awardees.
• Rapid City Regional Hospital, in addition to coordinating the
state programs mentioned previously, established collabora-
tions with the Native American Cancer Research Corporation
(NACR-PI Linda Burhansstipanov, DrPH), the University of
Washington-Seattle (Dedra Buchwald, MD), Marquette Uni-
versity (Sheikh Iqbal Ahamed, PhD), and the University of New
Mexico (Emily Haozous, PhD) to increase cancer screening and
palliative care programs in the remote reservations for AIs.
In addition, two resident physicians from Harvard University
performed their research year at RCRH: Ashleigh Guadagnolo,
MD, MPH (radiation oncology) and Sunshine Dwojak, MD
(head and neck surgery). RCRH was awarded a 4-year NCI
Provocative Questions R01 grant in 2012 by leveraging their
CRRs to implement an “American Indian mHealth Smoking
Dependency Study” program for the AIs in South Dakota. Sev-
eral publications resulted from these collaborations with the
WFP that ultimately assisted with program sustainability (4–6,
19–21).
• Coastal Carolina Radiation Oncology (CCRO) used their CDRP
success in patient accrual to become a full member of NRG
Oncology. To sustain their disparity program, CCRO again
partnered with NHRMC to form the Southeastern North Car-
olina (SENC) CCOP, a grant that was awarded in 2013. Because
the minority population in SENC is <50% of the population,
the SENC CCOP could not apply to become a new NCI’s
Community Oncology Research Program (NCORP) Minor-
ity/Underserved Community Site in 2014. Instead, CCRO will
revert to full membership in NRG, while NHRMC will likely be
an affiliate member of the Alliance group.
• Singing River Health System is building on their mentor rela-
tionship with University of Alabama Birmingham (UAB) Can-
cer Center. It will expand their current patient navigation
program via participation as the only Mississippi-based site
participating in the CMS Health Care Innovation Challenge
award – Deep South Cancer Navigation Network and will receive
$1 million over 3 years to support 3.5 FTEs for their patient
navigation Program.
Philanthropy is another means of potential support, but com-
munity resources that major cancer centers or cooperative groups
have are not accessible in these health disparities communities.
For them to raise sufficient funding to sustain their infrastruc-
ture and professional staff and become competitive for the major
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infrastructure, clinical trials and center grants available are not a
reasonable expectation.
CONCLUSION
Through the CDRP program, clinical trials were established in
health disparities sites not previously participating in the NCI
clinical trials enterprise. The initial success of this pilot program is
reassuring and may lead to improved general healthcare awareness
for their minority/underserved populations and an increase in the
diversity in NCI clinical trials.
Health disparity is an economic issue as much as a “minority”
issue. Some health disparities regions have unique populations
(i.e., the AIs) and when the study of the biological basis of cancer
is conducted for their benefit, trust can be established and “preci-
sion/personalized” medicine targeting their illnesses can then be
investigated.
The BSA review of the program renewal raised the issue of
moral obligation for sustaining programs. Federal agencies sup-
port all of the people and the CRCHD has emphasized the large
potential value of applying what we already know to help improve
cancer outcomes for health disparities communities. While some
of what CDRP accomplished met the standard metrics of clini-
cal research as judged by participation numbers, there are aspects
that were indeed unique and fall within implementation science.
Lessons learned are applicable to future programs. In regard to the
moral issue, research programs must pass peer review but, per-
haps, different metrics are justified for the disparities sites that
suffer from a lack of infrastructure and experience when com-
peting for grants. For all the sites, especially the three 10-year
awardees, the CDRP program succeeded in bringing people to
clinical trials who previously were on the periphery and with-
out access to the potential advances from these studies. This
pilot program showed that reaching health disparities communi-
ties who are new to cancer research can be done and the future
challenge is not only to broaden access to appropriate cancer
care for health disparities populations, but also to sustain these
gains.
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